Companies › Beijing Health Guard Biotechnology
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H Recombinant nonavalent HPV vaccine targeting 9 HPV types | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Human Papillomavirus Infection | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05662020 | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (H | Phase 3 | Human Papillomavirus Infection | Infectious disease | Mar 2028 |
Merck & Co. (MSD) Shanghai Bovax Biotechnology National Vaccine and Serum Institute, China
National Vaccine and Serum Institute, China Shanghai Bovax Biotechnology CastleVax Medicago Brii Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.